Tashkent, Uzbekistan (UzDaily.com) -- The Ministry of Health of the Republic of Uzbekistan approved the use of an inhaled glucocorticosteroid by the international biopharmaceutical company AstraZeneca for the treatment of false croup (stenosing laryngotracheitis) in children. Thus, a new emergency therapy for acute stenosing laryngotracheitis has become available to the residents of the republic.

False croup is the most common cause of acute upper airway obstruction in children aged 6 months to 6 years. Often, symptoms quickly stop - in 60% of cases with adequate therapy, their resolution occurs within 48 hours. However, about 5% of children with croup require hospitalization, and 1-3% of those hospitalized may need mechanical ventilation.

Today, in many countries, inhaled glucocorticosteroids, which relieve inflammation of the larynx, form the basis for the treatment of croup. Often, special devices are used for their use - nebulizers, they help to deliver the drug correctly, while not requiring effort from the child.

Entering the respiratory tract, the drug has a local anti-inflammatory effect, including a pronounced vasoconstrictor effect5. Therapy with AstraZeneca inhaled glucocorticosteroid reduces the length of stay in the hospital for children with mild to moderate severity of acute stenosing laryngotracheitis - 44% of patients who received the drug were discharged home after four hours of observation.

In addition to the hospital, the drug, when prescribed by a specialist, can be used at home, this allows you to refuse hospitalization and helps reduce the burden on the healthcare system.